Sexually Transmitted Diseases, Viral News

Sexually Transmitted Diseases, Viral	Welcome, Profile Billing Logout

«1 2...11 12 13 14 151617 18 19 20 21...49 50 »

||||||||||  daclatasvir/sofosbuvir / Generic mfg.
Trial completion, Combination therapy, IO biomarker:  A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. (clinicaltrials.gov) -  Feb 9, 2015
P3, N=203, Completed,  Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed

||||||||||  vicriviroc (MK-7690) / Merck (MSD)
Phase classification:  Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Na (clinicaltrials.gov) -  Feb 6, 2015
P2, N=218, Completed,  Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Phase classification: P3 --> P2

|||||||||| Enrollment open, Trial primary completion date: Evaluation of Enhanced Syphilis Screening Among HIV-positive Men (clinicaltrials.gov) - Feb 6, 2015
P=N/A, N=3131, Recruiting, Sponsor: Ontario HIV Treatment Network
Phase classification: P3 --> P2 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2016 --> Jul 2017

|||||||||| Trial primary completion date: Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=100, Recruiting, Sponsor: AIDS Malignancy Clinical Trials Consortium
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2016 --> Jul 2017 Trial primary completion date: Dec 2014 --> Aug 2015

|||||||||| Trial primary completion date: Tuberculosis Recurrence Upon Treatment With Highly Active Antiretroviral Therapy (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=402, Active, not recruiting, Sponsor: Centre for the AIDS Programme of Research in South Africa
Trial primary completion date: Dec 2014 --> Aug 2015 Trial primary completion date: May 2013 --> May 2016

||||||||||  Selzentry (maraviroc) / ViiV Healthcare
Trial primary completion date:  Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA) (clinicaltrials.gov) -  Feb 5, 2015
P4, N=330, Recruiting,  Sponsor: Catholic University of the Sacred Heart
Trial primary completion date: May 2013 --> May 2016 Trial primary completion date: May 2015 --> Mar 2016

|||||||||| Trial completion: RHIVA: Reducing HIV in Adolescents (clinicaltrials.gov) - Feb 5, 2015
P2, N=3217, Completed, Sponsor: Centre for the AIDS Programme of Research in South Africa
Trial primary completion date: May 2015 --> Mar 2016 Active, not recruiting --> Completed

||||||||||  Isentress (raltegravir) / Merck (MSD)
Trial completion, Adverse events:  Raltegravir Switch for Toxicity or Adverse Events (clinicaltrials.gov) -  Feb 5, 2015
P2b, N=40, Completed,  Sponsor: Catholic University of the Sacred Heart
Active, not recruiting --> Completed Recruiting --> Completed

|||||||||| Enrollment open: DVD-based HIV/HCV Prevention Intervention for Drug-Involved Latino Criminal Justice Clients (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=210, Recruiting, Sponsor: University of Delaware
Recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed, Trial primary completion date:  DOL-ART: A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (clinicaltrials.gov) -  Feb 2, 2015
P=N/A, N=411, Active, not recruiting,  Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jun 2017

|||||||||| Trial primary completion date: Traditional Complementary and Alternative Medicine (CAM) Therapy in the Treatment of HIV/AIDS (clinicaltrials.gov) - Jan 30, 2015
P3, N=1000, Recruiting, Sponsor: Traditional Alternative Medicine Research, India
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jun 2017 Trial primary completion date: Feb 2015 --> Feb 2017

||||||||||  rosuvastatin / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, IO biomarker:  Effect of Rosuvastatin on Endothelial Function (clinicaltrials.gov) -  Jan 29, 2015
P2/3, N=7, Terminated,  Sponsor: University of Hawaii
Trial primary completion date: Feb 2015 --> Feb 2017 N=20 --> 7 | Recruiting --> Terminated | Trial primary completion date: Aug 2013 --> Jan 2015; poor enrollment

||||||||||  rifampicin / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P4 trial:  Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB (clinicaltrials.gov) -  Jan 28, 2015
P4, N=90, Recruiting,  Sponsor: Drugs for Neglected Diseases

||||||||||  Vocabria (cabotegravir oral) / ViiV Healthcare
New P3 trial:  Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir (clinicaltrials.gov) -  Jan 26, 2015
P3, N=36, Not yet recruiting,  Sponsor: ViiV Healthcare

|||||||||| Enrollment closed: BRYOLAT: Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment (clinicaltrials.gov) - Jan 26, 2015
P1, N=12, Active, not recruiting, Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
N=20 --> 7 | Recruiting --> Terminated | Trial primary completion date: Aug 2013 --> Jan 2015; poor enrollment Recruiting --> Active, not recruiting

||||||||||  Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion:  Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (clinicaltrials.gov) -  Jan 26, 2015
P3, N=439, Completed,  Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion:  Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (clinicaltrials.gov) -  Jan 26, 2015
P3, N=438, Completed,  Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial primary completion date: Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study (clinicaltrials.gov) - Jan 22, 2015
P3, N=72, Active, not recruiting, Sponsor: Institute of Tropical Medicine, Belgium
Active, not recruiting --> Completed Trial primary completion date: Aug 2014 --> Aug 2015

||||||||||  Vitekta (elvitegravir) / Japan Tobacco, Gilead
Enrollment change, Trial primary completion date, Combination therapy:  Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection (clinicaltrials.gov) -  Jan 22, 2015
P2, N=192, Active, not recruiting,  Sponsor: Gilead Sciences
Trial primary completion date: Aug 2014 --> Aug 2015 N=122 --> 192 | Trial primary completion date: Jan 2015 --> Apr 2015

||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Clinical:  TRIUMPH: Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany (clinicaltrials.gov) -  Jan 22, 2015
P=N/A, N=400, Not yet recruiting,  Sponsor: ViiV Healthcare

||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P1 trial:  HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection (clinicaltrials.gov) -  Jan 22, 2015
P1, N=13, Not yet recruiting,  Sponsor: Fred Hutchinson Cancer Research Center

|||||||||| Enrollment open, Trial initiation date: MICROGUT: Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients (clinicaltrials.gov) - Jan 20, 2015
P=N/A, N=100, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
N=122 --> 192 | Trial primary completion date: Jan 2015 --> Apr 2015 Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Dec 2014

|||||||||| Clinical: Accuracy of Portable Colposcopy and HPV Genotypes Among HIV+ Women (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=500, Not yet recruiting, Sponsor: Duke University

|||||||||| New P1/2 trial: Eliciting Affect in Teens in a Virtual World (Project AVATAR) (clinicaltrials.gov) - Jan 15, 2015
P1/2, N=100, Recruiting, Sponsor: Rhode Island Hospital

||||||||||  Pegasys (pegylated interferon ? -2a) / Roche, Roferon A (recombinant interferon alfa-2a) / Roche
Trial completion, IO biomarker:  HB01EMVIPEG: Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients (clinicaltrials.gov) -  Jan 15, 2015
P2/3, N=56, Completed,  Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Dec 2014 Active, not recruiting --> Completed

|||||||||| Trial completion: HIV Prevention for Youth With Severe Mental Illness (clinicaltrials.gov) - Jan 13, 2015
P1, N=718, Completed, Sponsor: Rhode Island Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  atorvastatin / Generic mfg.
Trial completion:  Statin Therapy to Improve Atherosclerosis in HIV Patients (clinicaltrials.gov) -  Jan 12, 2015
P=N/A, N=40, Completed,  Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: Therapeutic Schools: Affect Management and HIV Prevention (clinicaltrials.gov) - Jan 12, 2015
P1, N=420, Completed, Sponsor: Rhode Island Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: Alcohol Harm Reduction Intervention Among Female Sex Workers in Mombasa, Kenya (clinicaltrials.gov) - Jan 9, 2015
P=N/A, N=818, Completed, Sponsor: FHI 360
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  HSV vaccine (GEN-003) / Genocea, Shionogi
Enrollment open:  Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study (clinicaltrials.gov) -  Jan 8, 2015
P2, N=45, Enrolling by invitation,  Sponsor: Genocea Biosciences, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Enrolling by invitation

|||||||||| Trial primary completion date: BRM4: The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV (clinicaltrials.gov) - Jan 6, 2015
P=N/A, N=40, Recruiting, Sponsor: University of Miami
Not yet recruiting --> Enrolling by invitation Trial primary completion date: Dec 2015 --> Jul 2016

|||||||||| Trial completion: EP48 HIV CHEST: Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study (clinicaltrials.gov) - Jan 2, 2015
P=N/A, N=450, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Trial primary completion date: Dec 2015 --> Jul 2016 Active, not recruiting --> Completed

|||||||||| Trial completion: Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome (clinicaltrials.gov) - Jan 2, 2015
P=N/A, N=52, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date:  Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection (clinicaltrials.gov) -  Dec 24, 2014
P3, N=300, Active, not recruiting,  Sponsor: Gilead Sciences
Active, not recruiting --> Completed Trial primary completion date: Mar 2015 --> Nov 2015

|||||||||| Enrollment change: Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection (clinicaltrials.gov) - Dec 24, 2014
P1/2, N=56, Completed, Sponsor: Bayer
Trial primary completion date: Mar 2015 --> Nov 2015 N=82 --> 56

||||||||||  Isentress (raltegravir) / Merck (MSD)
Enrollment closed, Trial primary completion date, Combination therapy:  onceMRK: Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA (clinicaltrials.gov) -  Dec 24, 2014
P3, N=750, Active, not recruiting,  Sponsor: Merck Sharp & Dohme Corp.
N=82 --> 56 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jan 2016

||||||||||  Bydureon (exenatide XR once-weekly) / AstraZeneca
Trial completion, Enrollment change, Trial primary completion date:  Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults (clinicaltrials.gov) -  Dec 24, 2014
P4, N=6, Completed,  Sponsor: Vanderbilt University
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jan 2016 Not yet recruiting --> Completed | N=12 --> 6 | Trial primary completion date: Aug 2013 --> Dec 2014

|||||||||| Trial completion, Enrollment change: A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects (clinicaltrials.gov) - Dec 24, 2014
P1/2, N=15, Completed, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Completed | N=12 --> 6 | Trial primary completion date: Aug 2013 --> Dec 2014 Active, not recruiting --> Completed | N=21 --> 15

|||||||||| IO biomarker: ANRSHBEP03: Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination (clinicaltrials.gov) - Dec 23, 2014
P=N/A, N=55, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

|||||||||| HEOR, Adherence: HOST: Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAART (clinicaltrials.gov) - Dec 23, 2014
P=N/A, N=650, Recruiting, Sponsor: Triple O Research Institute PA

||||||||||  NN1213 / Novo Nordisk
Trial completion:  Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection (clinicaltrials.gov) -  Dec 22, 2014
P1/2, N=56, Completed,  Sponsor: Bayer
Active, not recruiting --> Completed | N=21 --> 15 No longer recruiting --> Completed

||||||||||  AGS-004 / CoImmune
Trial primary completion date, IO biomarker:  Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption (clinicaltrials.gov) -  Dec 19, 2014
P2b, N=42, Active, not recruiting,  Sponsor: Argos Therapeutics
No longer recruiting --> Completed Trial primary completion date: Apr 2014 --> Aug 2014

|||||||||| Trial completion: Antiretrovirals and Rate of Progression in Carotid Artery Intima-medial Thickness in HIV (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=120, Completed, Sponsor: University Hospital Case Medical Center
Trial primary completion date: Apr 2014 --> Aug 2014 Active, not recruiting --> Completed

||||||||||  trimethoprim/sulfamethoxazole / Generic mfg.
Enrollment open:  Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2) (clinicaltrials.gov) -  Dec 17, 2014
P3, N=200, Recruiting,  Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  Victrelis (boceprevir) / Roche, Merck (MSD)
Enrollment closed, Trial primary completion date:  Dutch Acute HCV in HIV Study (DAHHS) (clinicaltrials.gov) -  Dec 17, 2014
P2, N=60, Active, not recruiting,  Sponsor: Erasmus Medical Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Mar 2015

||||||||||  Vocabria (cabotegravir oral) / ViiV Healthcare
Trial completion:  Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects (clinicaltrials.gov) -  Dec 17, 2014
P1, N=20, Completed,  Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Mar 2015 Active, not recruiting --> Completed

|||||||||| Trial completion: LSTART: Multi-level Determinants of Starting ART Late: Aim 3 (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=1214, Completed, Sponsor: Columbia University
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: LSTART: Multi-level Determinants of Starting ART Late: Aim 2 (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=136, Completed, Sponsor: Columbia University
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial primary completion date: Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions (clinicaltrials.gov) - Dec 13, 2014
P=N/A, N=500, Recruiting, Sponsor: Valme University Hospital
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Sep 2015

||||||||||  GSK2838232 / GSK
Enrollment open:  A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects (clinicaltrials.gov) -  Dec 13, 2014
P1, N=20, Recruiting,  Sponsor: GlaxoSmithKline
Trial primary completion date: Sep 2014 --> Sep 2015 Not yet recruiting --> Recruiting



	Diseases Companies Products Productz Mechanisms of Action Sites